UBS Reiterates Buy on Alexion Pharma (ALXN) Following 4Q EPS Beat

February 4, 2016 8:39 AM

UBS maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $200.00 (from $222.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found